Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

The movie is based on the true story of two British athletes competing in the 1924 Summer Olympics in Paris. Englishman Harold Abrahams (Ben Cross), who is Jewish, overcomes anti-Semitism and class prejudice in order to compete against the "Flying Scotsman", Eric Liddell (Ian Charleson), in the 100 metre race.Opening in 1919 England, Harold Abrahams enters Cambridge University, where he meets with anti-Semitism from the staff, but enjoys participating in the Gilbert and Sullivan theatre club. He becomes the first person to ever complete the Trinity Great Court run: running around the court in the time it takes for the clock to strike 12. Abrahams achieves an undefeated string of victories in various national running competitions. Although focused on his running, he falls in love with a famous Gilbert and Sullivan soprano, Sybil (Alice Krige).Meanwhile in Scotland, Eric Liddell (Ian Charleson), born in China of Scottish missionary parents, is in Scotland. His devout sister Jennie (Cheryl Campbell) disapproves of Liddell's plans to pursue competitive running. But Liddell sees running as a way of glorifying God before returning to China to work as a missionary.Abrahams and Liddell meet for the first time in London in June 1923 when they first race against each other in a British open. Liddell beats Abrahams who takes it extremely badly. But Sam Mussabini (Ian Holm), a professional trainer whom Abrahams had approached earlier, offers to take him on to improve his technique. This attracts criticism from the Cambridge college masters (John Gielgud and Lindsay Anderson). In their meeting with Abrahams, the Cambridge masters allege it is ungentlemanly for an amateur to "play the tradesman" by employing a professional coach. Abrahams realizes this is a cover for their anti-Semitism and class entitlement, and dismisses their concern.Meanwhile, when Liddell accidentally misses a church prayer meeting because of his running, his sister Jennie upbraids him and accuses him of no longer caring about God. But Eric tells her that though he intends to eventually return to the China mission, he feels divinely inspired when running, and that not to run would be to dishonor God: "I believe that God made me for a purpose. But He also made me fast, and when I run, I feel His pleasure."The two athletes, after over a year of training and racing, are accepted to represent Great Britain in the 1924 Summer Olympics in Paris, France. Also accepted are Abrahams' Cambridge buddies, Lord Andrew Lindsay (Nigel Havers), Aubrey Montague (Nicholas Farrell), and Henry Stallard (Daniel Gerroll) whom join the UK team.While boarding the boat to Paris for the Olympics, Liddell learns from the newspapers that the event for his 100 meter race will be on a Sunday. Liddell refuses to run the race despite strong pressure from the Prince of Wales (David Yelland) as well as the head of the British Olympic committee, Lord Cadogan (Patrick Magee) because Liddell's Christian convictions prevent him from running on the Christian Sabbath (Sunday).Hope appears in the form of Liddell's teammate Lord Andrew Lindsay. Having already won a silver medal in the 400 meter hurdles, Lindsay proposes to yield his place in the 400 meter race on the following Tuesday to Liddell. Liddell gratefully agrees. His religious convictions in the face of national athletic pride make headlines around the world.Liddell delivers a sermon at the Paris Church of Scotland that Sunday, and quotes from Isaiah 40, verse 31:"But they that wait upon the LORD shall renew their strength; they shall mount up with wings as eagles; they shall run, and be not weary; and they shall walk, and not faint."Meanwhile, Abrahams is badly beaten by the heavily favored and more experienced United States runner Charles Paddock (Dennis Christopher) in the 200 meter race who wins the gold medal, while Abrahams takes a second place silver medal. Abrahams knows that his last chance for a gold medal will be the 100 meter run. He competes in the 100 meter sprint and wins, beating Paddock and the rest of the Americans.On Tuesday, just before Liddell's race, the American coach remarks to his runners that Liddell has little chance
Who plays Eric Liddell?

This was a 12-week randomized, placebo-controlled trial to assess the efficacy of quetiapine monotherapy in the treatment of posttraumatic stress disorder (PTSD). Eighty patients were randomly assigned to treatment with either quetiapine or placebo. The primary outcome measure was the Clinician-Administered PTSD Scale (CAPS). Secondary efficacy measures included the CAPS subscales, the Davidson Trauma Scale, the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scales for severity of Illness and improvement, the Hamilton Depression Rating Scale (HAM-D), and the Hamilton Anxiety Rating Scale (HAM-A). Safety measurements included adverse events, vital signs, the Abnormal Involuntary Movement Scale, the Barnes Akathisia Scale, the Simpson-Angus Scale, and the Arizona Sexual Experiences Scale. After a 1-week placebo run-in, quetiapine was started at a daily dosage of 25 mg and increased to a maximum of 800 mg; the average was 258 mg (range, 50-800 mg). Reductions in CAPS total, re-experiencing, and hyperarousal scores were significantly greater for the quetiapine group than for the placebo group. Greater improvements were also observed for quetiapine in scores on the Davidson Trauma Scale, CGI severity and improvement ratings, PANSS positive symptom and general psychopathology subscales, HAM-A, and HAM-D than for placebo. Adverse events were generally mild and expected based on prior studies of quetiapine in this and other patient population. There were no differences in safety measures between groups. Quetiapine monotherapy was efficacious in the treatment of PTSD. These findings suggest quetiapine as a single agent is effective in treating military PTSD.
Symptoms of which disorder are evaluated with the Davidson Trauma Scale?

Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed. This is a review of the relevant literature regarding dasatinib development in CML (2003-2013). Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. Dasatinib is an effective treatment option for patients with CML.

What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?

